Medication info
Proca-van Capsule 25 mg (Pregabalin)

Proca-van Capsule 25 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›25mg / 1 capsule
Manufacturer / importer
Eden Pharma Co., Ltd.
Appearance
A hard capsule with a light yellow upper part and white lower part containing a white powder.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 202001648 · Approved 2020.03.10 · Insurance code 628901640

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. This medicine is excreted primarily by the kidneys; therefore, the dose should be adjusted in patients with renal impairment. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of administration’.) 2. Epilepsy Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of administration Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above equation by 0.85. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with renal impairment.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Eden Pharma Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is effective in treating pain caused by peripheral and central neuropathy in adults. It is also used as an adjunctive treatment for partial seizures in epilepsy patients, whether there are secondary generalized symptoms or not. Additionally, it helps alleviate the symptoms of fibromyalgia. It is widely utilized in various neurological disorders and contributes to improving the quality of life of patients.

How to take

Adult dose

Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. This medicine is excreted primarily by the kidneys; therefore, the dose should be adjusted in patients with renal impairment. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of administration’.) 2. Epilepsy Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of administration Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above equation by 0.85. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with renal impairment.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so if there are any changes in mood or behavior during use, patients must inform healthcare professionals immediately. Patients with allergies to the ingredients of this medication or certain genetic disorders should not use it. Diabetic patients should be cautious as weight gain may necessitate adjustments in the dosage of blood sugar control medications. If symptoms of angioedema (swelling of the face or around the mouth) occur, use should be discontinued immediately and medical attention sought. Elderly patients should be careful post-administration due to the risk of dizziness or drowsiness leading to falls or injuries. Some patients may experience blurred vision or changes in vision, and if these symptoms occur, they should consult a healthcare professional. Discontinuing this medication suddenly may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be gradually tapered as directed by a healthcare professional. This medication carries a risk of drug abuse, so patients with a history of substance abuse should be particularly vigilant and monitored for abnormal behavior. Patients with impaired kidney function may require dosage adjustments. Patients with severe cardiac conditions should use this medication with caution. When taken with other medications that have central nervous system depressant effects, there may be an increased risk of drowsiness or respiratory depression, so caution is required. In early pregnancy, there may be a risk of congenital malformations in the fetus, so women who are pregnant or planning to become pregnant should consult with healthcare professionals before use and should use effective contraception. Breastfeeding women should discuss with healthcare professionals whether to discontinue breastfeeding or the medication since it can be passed into breast milk. Activities that require concentration, such as driving or operating machinery, should be avoided until dizziness or drowsiness fully resolves. In the case of overdose, symptoms such as confusion, drowsiness, and seizures may occur, and medical attention should be sought immediately; blood dialysis may be required if necessary. Keep this medication out of the reach of children and avoid transferring it to another container. If severe rashes, swelling, or breathing difficulties occur, use should be stopped immediately and healthcare professionals informed.

Side effects

  • suicidal impulse
  • suicidal behavior
  • depression
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
  • loss of consciousness
Show 179 more
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual dysesthesia
  • restlessness
  • anxiety
  • mood swings
  • emotional lability
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attack
  • loss of control
  • apathy
  • ataxia
  • dyspraxia
  • equilibrium disorder
  • amnesia
  • attention deficit
  • memory impairment
  • tremor
  • speech impairment
  • sensory disturbance
  • decreased sensation
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language disorder
  • clonic tremor
  • hyporeflexia
  • motor abnormalities
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • stupor
  • kinetic impairment syndrome
  • olfactory disturbance
  • loss of taste
  • writing impairment
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • urinary retention
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling drunk
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • alanine aminotransferase increase
  • serum creatine phosphokinase increase
  • aspartate aminotransferase increase
  • blood sugar increase
  • platelet count decrease
  • serum potassium decrease
  • serum creatinine increase
  • white blood cell count decrease
  • hypersensitivity
  • allergic reaction
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • malaise
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • confused state
  • agitation
  • restlessness
  • convulsion
  • shock
  • anaphylaxis-like symptoms
  • Stevens-Johnson syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, preferably at room temperature between 15℃ and 30℃. Storing it this way helps maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

A hard capsule with a light yellow upper part and white lower part containing a white powder.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.